Practice Name. Audit Undertaken By and Job Title. Date of Audit
|
|
- Bridget Nash
- 5 years ago
- Views:
Transcription
1 Pregabalin Audit Template This template can be used to document the Pregabalin audit undertaken by practices as part of the Incentive Scheme. It has been produced to provide practices with a guide but may be adapted to suit the needs of the practice or individual audit. Practice Name Audit Undertaken By and Job Title Date of Audit Aim Background (Reason for audit being undertaken) To review a selected cohort of patients prescribed pregabalin in the practice and if appropriate, switch to a cost effective alternative or stop altogether. Pregabalin is an area of high cost prescribing and growth. Pregabalin prescribing costs Wirral CCG 1,460,625 million annually. Despite previous work in 2013 to reduce pregabalin prescribing, the CCG remains above the national average in terms of prescribing costs and items prescribed. Wirral guidelines for neuropathic pain now recommend pregabalin fourth line after amitriptyline, nortriptyline and gabapentin. They also recommend that conventional analgesics are tried first 1 Nortriptyline is more expensive than amitriptyline but better tolerated and is cheaper than gabapentin. Secondary care clinicians are keen that this second step is followed to avoid increasing the use of both gabapentin and pregabalin. Reducing prescribing by 10% in terms of cost could save 146K for the Wirral CCG. Audit Criteria/Audit Standard See Pregabalin Audit Sheet Audit Period (if different to audit The MM Team will review data in January Version 1.0 Page 1 of 6
2 date) Description of Method 2015 to determine if the target has been achieved. The MM team will also carry out a spot check on randomly selected patients within the cohort to ensure patients have been switched or stopped. Exclude patients who are prescribed pregabalin for diabetic neuropathy. Select a cohort of 20% of the remaining number of patients. Review this cohort of current patients prescribed pregabalin with a view to stopping medication altogether or changing patients to a cost effective alternative using current guidelines if deemed clinically appropriate. Results To be recorded using prescribing audit data sheet attached (pg 3) Action Plan (including timescales and need to re-audit) References 1. Wirral Clinical Guideline for the management of neuropathic pain 2. An update on the drug treatment of neuropathic pain Part 1 DTB 2012; 50(10): UKMi Q&A How do you switch between pregabalin and gabapentin for neuropathic pain, and vice versa? Toth C Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy. Pain Medicine 2010; 11: Version 1.0 Page 2 of 6
3 Pregabalin Audit Sheet Patient ID Types of pain &/or neuropathic pain recorded with dates Other relevant diagnosed conditions with dates Is the patient under secondary care for pain? Please record speciality e.g. chronic pain team, orthopaedics. Is the patient under secondary care for other conditions? Yes/No Date of last contact Yes/No Date of last contact Pain history, including drugs prescribed, with dates Results of pain assessments and reviews with dates Current pain medication with doses and date started Compliance with pain medication Renal function (egfr) with date Possible action ie Switch/Stop/Optimise Dose Audited by: Date of audit: Version 1.0 Page 3 of 6
4 Summary of Findings Pregabalin Audit Practice name.date of Audit Summary of Actions Total number of patients prescribed pregabalin. Number of patients prescribed pregabalin (excluding diabetic peripheral neuropathy). These are the eligible patients for the audit. Number of patients in audited cohort (20% of above total) Number of patients stopped Number of patients switched to cost effective alternative Number of patients for whom dose was optimised Version 1.0 Page 4 of 6
5 Appendix 1 Dosing Information Gabapentin Dosing Information for an increasing dose Gabapentin can be given with or without food and should be swallowed whole with sufficient fluidintake (e.g. a glass of water). Standard schedule Day 1 Day 2 Day 3 Day 4 Day 5 Morning 300mg 300mg 300mg 300mg Midday 300mg 300mg 300mg Night 300mg 300mg 300mg 300mg 600mg Day 6 Day 7 Day 8 Day 9 Day 10 Morning 300mg 300mg 300mg 600mg 600mg Midday 300mg 600mg 600mg 600mg 600mg Night 600mg 600mg 600mg 600mg 600mg Accelerated schedule Day 1 Day 2 Day 3 Day 4 Day 5 Morning 300mg 300mg 300mg 300mg 300mg Midday 300mg 300mg 300mg 300mg 600mg Night 300mg 300mg 600mg 600mg 600mg Day 6 Day 7 Day 8 Day 9 Day 10 Morning 300mg 600mg 600mg 600mg 600mg Midday 600mg 600mg 600mg 600mg 600mg Night 600mg 600mg 600mg 900mg 900mg Based on individual patient response and tolerability, the dose can be further increased in 300 mg/day increments every 2-3 days up to a maximum dose of 3600 mg/day. Slower titration of gabapentin dosage may be appropriate for individual patients. The minimum time to reach a dose of 1800 mg/day is one week, to reach 2400 mg/day is a total of 2 weeks, and to reach 3600 mg/day is a total of 3 weeks. 2 Elderly patients (over 65 years) and patients with compromised renal function may require dosage adjustment because of declining renal function. Somnolence, peripheral oedema and asthenia may be more frequent in elderly patients. Gabapentin dose adjustment based on renal function Creatinine Clearance (ml/min) or egfr Total Daily Dose (mg/day) * -600 Version 1.0 Page 5 of 6 <15** 150 * -300 *To be administered as 300 mg every other day. ** For patients with creatinine clearance <15 ml/min, the daily dose should be reduced in proportion to creatinine clearance (e.g., patients with a creatinine clearance of 7.5 ml/min should receive one-half the daily dose that patients with a creatinine clearance of 15 ml/min receive). Gabapentin 100 mg capsules can be used to follow dosing recommendations for patients with renal insufficiency
6 Switching pregabalin to gabapentin in patients with normal renal function 3 This would be a straight switch, rather than titrating down the pregabalin dose and titrating up the gabapentin dose. Pregabalin total daily dose pre-switch Gabapentin total daily dose post switch (Toth study 4 ) Suggested daily dose of gabapentin 150mg 900mg 300mg tds 225mg 901mg to 1500mg 400mg tds 300mg 1501mg to 2100mg 2x300mg tds 450mg 2101mg to 2700mg 2x400mg tds 600mg 2701mg to 3600mg 3x300mg tds For daily doses of pregabalin below 150mg daily, e.g. 100mg, 75mg switch to gabapentin 100mg tds, and titrate up if necessary. Discontinuing gabapentin If gabapentin has to be discontinued it is recommended this should be done gradually over a minimum of 1 week (SPC). Stepping down and discontinuing pregabalin The SPC for Lyrica states that pregabalin should be discontinued gradually over at least one week, independent of the indication. NHS Gloucestershire recommends reducing the dose by 50-75mg per week 0Web%20Documents/Pregabalin%20review%20(neuropathic%20pain)%20mg%204%20(2).pdf Suggested withdrawal schedule for a dose of 150mg bd (based on table from above reference): Week 1 Week 2 Week 3 Week 4 Stop and Morning 150mg 75mg 50mg 25mg review Evening 75mg 75mg 50mg 25mg patient Version 1.0 Page 6 of 6
How to switch from gabapentin to lyrica
How to switch from gabapentin to lyrica Search UKMi Switching between Pregabalin and Gabapentin for 29 Nov 2012 How do you switch between pregabalin and gabapentin for neuropathic pain, and vice versa?.
More informationNeuropathic Pain Treatment Guidelines
Neuropathic Pain Treatment Guidelines Background Pain is an unpleasant sensory and emotional experience that can have a significant impact on a person s quality of life, general health, psychological health,
More informationPRIMARY MANAGEMENT OF DRUG PRESCRIBING IN NON-MALIGNANT PAIN
NORTH OF TYNE GUIDELINES FOR: PRIMARY MANAGEMENT OF DRUG PRESCRIBING IN NON-MALIGNANT PAIN (EXCLUDING DETAILED RECOMMENDATIONS FOR LONG TERM STRONG OPIATES) February 2015 (minor update April 2017) 1 CONTENTS
More informationNeuropathic pain MID ESSEX LOCALITY
Neuropathic pain Neuropathic pain is defined as pain caused by a lesion or disease of the somatosensory nervous system. A. Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) i Read questions to
More informationPregabalin Prescribing in Primary Care Audit Results 2012/13
Executive summary Pregabalin Prescribing in Primary Care Audit Results 2012/13 Pregabalin is extensively used across Aneurin Bevan Health Board (ABHB). It is the second highest medicine in terms of primary
More informationPain Management Documents
Pain Management Documents Prescriber and Patient Resources Non-cancer Pain Guidance Neuropathic Pain Guidance Stopping or Switching low strength Buprenorphine Patches Red and Yellow Flags Medicines Management
More informationMedicines Optimisation Team Standard Operating procedure for Alogliptin Audit:
Medicines Optimisation Team Standard Operating procedure for Alogliptin Audit: To review type 2 diabetic patients prescribed dipedtidylpeptidase-4 (DPP-4) inhibitors (linagliptin (Trajenta, saxagliptin
More informationCONCORD INTERNAL MEDICINE. Peripheral Neuropathy. April 22, 2012
CONCORD INTERNAL MEDICINE Peripheral Neuropathy Douglas G. Kelling, Jr., MD C. Gismondi-Eagan, MD, FACP George C. Monroe, III, MD April 22, 2012 The information contained in this protocol should never
More informationLyrica. Lyrica (pregabalin) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.18 Subject: Lyrica Page: 1 of 6 Last Review Date: June 22, 2017 Lyrica Description Lyrica (pregabalin)
More informationImmediate Release Nifedipine Review July 2011
Title of Project: NHS Dumfries & Galloway - Clinical Safety Review Immediate Release Nifedipine Review July 2011 1 Reason for the review 2 Aim Immediate release nifedipine capsules are associated with
More informationNHS Dumfries & Galloway Ferrous Salt Review Protocol November 09
Title of Project: NHS Dumfries & Galloway Ferrous Salt Review Protocol November 09 1 Reason for the review Choice of iron preparation is based on cost and incidence of side effects (BNF). There is little
More informationNEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES
NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES GENERAL PRINCIPLES Neuropathic pain may be relieved in the majority of patients by multimodal management A careful history and examination are essential.
More informationGABAPENTIN BNF Gabapentin is a chemical analogue of γ-aminobutyric acid (GABA) but does not act
GABAPENTIN BNF 4.8.1 Class: Anti-epileptic. Indications: Adjunctive treatment for partial seizures with or without secondary generalisation; 1,2 neuropathic pain of any cause. 3 12 Pharmacology Gabapentin
More informationScottish Medicines Consortium
Scottish Medicines Consortium duloxetine 30mg and 60mg capsules (Cymbalta ) No. (285/06) Eli Lilly and Company Limited/Boehringer Ingelheim 4 August 2006 The Scottish Medicines Consortium has completed
More informationBACKGROUND Measuring renal function :
A GUIDE TO USE OF COMMON PALLIATIVE CARE DRUGS IN RENAL IMPAIRMENT These guidelines bring together information and recommendations from the Palliative Care formulary (PCF5 ) BACKGROUND Measuring renal
More informationGateshead Pain Guidelines for Chronic Conditions
Gateshead Pain Guidelines for Chronic Conditions Effective Date: 13.2.2013 Review Date: 13.2.2015 Gateshead Pain Guidelines: Contents PAIN GUIDELINES Chronic Non-Malignant Pain 5 Musculoskeletal Pain 6
More informationManagement of neuropathic pain (non-malignant) Medicines Initiation Protocol
Introduction Management of neuropathic pain (non-malignant) Medicines Initiation Protocol Pain is one of the most common reasons that patients present to Primary Care It is known that there are widespread
More informationNeuropathic pain (pain due to nerve damage)
Neuropathic pain (pain due to nerve damage) Clinical Guideline Pain can be nociceptive, neuropathic or mixed. The neuropathic component of pain generally responds poorly to conventional analgesics. Consider
More informationQ&A: Opioid Prescribing for Chronic Non-Malignant Pain
NHS Hastings and Rother Clinical Commissioning Group Chair Dr David Warden Chief Officer Amanda Philpott NHS Eastbourne, Hailsham and Seaford Clinical Commissioning Group Chair Dr Martin Writer Chief Officer
More informationLyrica. Lyrica, Lyrica CR (pregabalin) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.18 Subject: Page: 1 of 7 Last Review Date: March 16, 2018 Description, CR (pregabalin) Background
More informationCommissioning Policy Individual Funding Request
Commissioning Policy Individual Funding Request Referrals to Secondary Care Pain Services for Assessment and Treatment Criteria Based Access Policy Date Adopted: Version: Development Individual Funding
More informationAnalgesia in patients with impaired renal function Formulary Guidance
Analgesia in patients with impaired renal function Formulary Guidance Approved by Trust D&TC: January 2010 Revised March 2017 Contents Paragraph Page 1 Aim 4 2 Introduction 4 3 Assessment of renal function
More informationVolume 9; Number 3 March 2015 PRESCRIBING AND DISPENSING PREGABALIN FOR NEUROPATHIC PAIN
Arden and Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and
More informationAdvice following an Independent Review Panel (IRP)
Scottish Medicines Consortium Advice following an Independent Review Panel (IRP) Pregabalin 25, 50, 75, 100, 150, 200 and 300mg capsules (Lyrica ) Pfizer No. 157/05 7 July 2006 The Scottish Medicines Consortium
More information7 th November % of patients had lidocaine plasters prescribed for the licensed indication of post herpatic neuralgia
Directorate of Integrated Care Health and Social Care Board 12-22 Linenhall Street Belfast BT2 8BS Tel : 028 90553782 Fax : 028 90553622 Web Site: www.hscboard.hscni.net 7 th November 2013 Dear colleague
More informationGuidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults
Guidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults Ref: PHARM-0025-v3 Status: FINAL Document type: Guidelines Guidance on Safe Prescribing of Melatonin Page
More informationDocument Title Pharmacological Management of Generalised Anxiety Disorder
Document Title Pharmacological Management of Generalised Anxiety Disorder Document Description Document Type Policy Service Application Trust Wide Version 1.1 Policy Reference no. POL 201 Lead Author(s)
More informationBNSSG Shared Care Guidance Please complete all sections
NHS Bristol CCG NHS North Somerset CCG NHS South Gloucestershire CCG North Bristol NHS Trust University Hospitals Bristol NHS Foundation Trust Weston Area Health NHS Trust BNSSG Shared Care Guidance Please
More informationInterprofessional Primary Care Medical Directive for Smoking Cessation
Insert Logo or Org Name Here Interprofessional Primary Care Medical Directive for Smoking Cessation Adapted from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 14,
More informationTitle of Project: NHS Dumfries & Galloway Respiratory Bundle Asthma: Bronchodilator Overuse Review April 2015
Title of Project: NHS Dumfries & Galloway Respiratory Bundle Asthma: Bronchodilator Overuse Review April 2015 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate
More informationGabapentin. Information for Pain Clinic patients
Gabapentin Information for Pain Clinic patients Who is this leaflet for? Your doctor has suggested that you try Gabapentin to help you to manage your pain condition. This leaflet explains how Gabapentin
More informationNHS Dumfries & Galloway Erectile Dysfunction Audit October 2010
Title of Project: NHS Dumfries & Galloway Erectile Dysfunction Audit October 2010 1 Reason for the review 1. To clarify the indications for erectile dysfunction. 2. To prescribe the formulary choice vardenafil
More informationGuidelines for the Management of Chronic Non-Malignant Pain (CNMP) in Primary Care (not including neuropathic pain (NeP).
Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG) North East Hampshire & Farnham CCG and Crawley, Horsham & Mid-Sussex CCG Guidelines for the
More informationGuidelines for the Pharmacological Management of Chronic Pain in Primary Care. December 2012
Guidelines for the Pharmacological Management of Chronic Pain in Primary Care December 2012 NHS Portsmouth CCG Fareham and Gosport CCG South Eastern Hampshire CCG 1 Guidelines for the Pharmacological Management
More informationTRANSPARENCY COMMITTEE OPINION. 18 March 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 March 2009 REQUIP LP 2 mg extended-release tablet Box of 21 tablets (CIP: 379 214-8) Box of 28 tablets (CIP: 379
More informationNHS West Cheshire Clinical Commissioning Group does not fund the prescribing for dental conditions on FP10.
PRESCRIBING COMMISSIONING POLICY: DENTAL CONDITIONS NHS West Cheshire Clinical Commissioning Group does not fund the prescribing for dental conditions on FP10. Note: Patients who are not eligible for treatment
More informationAppropriate prescribing of Oxycodone for non-cancer pain in general practice
CLINICAL AUDIT Appropriate prescribing of Oxycodone for non-cancer pain in general practice Valid to October 2022 bpac nz better medicin e Background Oxycodone is a strong opioid that milligram for milligram
More informationRef. Version Supersedes Approved for Date approved Document Owner N/A MMT 17/01/2017 Lois Taylor. Switching to Alogliptin (Vipidia )
Ref. Version Supersedes Approved for Date approved Document number use by Owner 001 1.0 N/A MMT 17/01/2017 Lois Taylor Aim: Switching to Alogliptin (Vipidia ) To reduce our spend on gliptins (DDP-4 drugs)
More informationProduct Cost per Pack Cost per 28 days (assuming 2 sprays od) Flixonase years 50mcg in both nostrils od (increasing to max bd prn)
Protocol for Flixonase to Avamys Nasal Spray Switch May 2010 1. Reason Avamys contains the corticosteroid fluticasone furoate (27.5mcg/spray) and Flixonase nasal spray contains fluticasone propionate (50mcg/spray).
More informationTRANSPARENCY COMMITTEE OPINION. 9 May 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 May 2007 LYRICA 25 mg capsules Pack of 56 capsules (CIP: 365 127-0) Pack of 84 capsules (CIP: 365 135-3) Pack of
More informationPersistent Pain in Secure Environments Health and Justice Pharmacy Network Meeting Tuesday 18 March 2014
Persistent Pain in Secure Environments Health and Justice Pharmacy Network Meeting Tuesday 18 March 2014 Dr Iain Brew Vice Chair RCGP SEG Health & Justice CRG Member Special Considerations General reluctance
More informationrequesting information regarding prescribing incentive schemes in Canterbury and Coastal Clinical Commissioning Group
requesting information regarding prescribing incentive schemes in Canterbury and Coastal Clinical Commissioning Group Canterbury and Coastal Clinical Consortium Group Medicine Management plans 2013/14
More informationScottish Medicines Consortium
Scottish Medicines Consortium pregabalin, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg capsules (Lyrica ) No. (389/07) Pfizer Limited 6 July 2007 The Scottish Medicines Consortium has completed
More informationThe Management of Overactive Bladder Syndrome with Antimuscarinic Drugs
The Management of Overactive Bladder Syndrome with Antimuscarinic Drugs Author Version Date Consultation Date of Ratification By JPG Shaista Hussain Joint Formulary Pharmacist V2 16.09.2014 Homerton University
More information2 Summary of NICE TA 249: Atrial fibrillation - Dabigatran Etexilate
Service Notification in response to DHSSPS endorsed NICE Technology Appraisals NICE TA 249: Atrial fibrillation - Dabigatran Etexilate 1 Name of Commissioning Team Long Term Conditions Commissioning Team
More informationPatient Group Direction for the Supply of Varenicline (Champix ) by Authorised Community Pharmacists
Patient Group Direction for the Supply of Varenicline (Champix ) This Patient Group Direction (PGD) is a specific written instruction for the supply of varenicline to groups of patients who may not be
More informationQuick Guide to Common Antidepressants-Adults
Quick Guide to Common Antidepressants-Adults Medication Therapeutic Range (mg/day) Initial Suggested Serotonin Reuptake Inhibitors (SSRIs) All available as generic FLUOXETINE (Prozac) CITALOPRAM (Celexa
More informationSIFROL â. Contraindications Hypersensitivity to pramipexole or any other component of the product.
SIFROL â Composition 1 tablet contains 0.088, 0.18 & 0.7 mg (S) 2 amino 4,5,6,7-tetrahydro-6-propylamino-benzothiazole (= pramipexole base) equivalent to 0.125, 0.25 & 1 mg of pramipexole dihydrochloride
More informationCosting statement: chronic idiopathic constipation - Lubiprostone
Putting NICE guidance into practice Costing statement: chronic idiopathic constipation - Lubiprostone Implementing the NICE guidance on Lubiprostone for treating chronic idiopathic constipation (TA318)
More informationMetformin MR to low cost branded generic (Sukkarto SR) Switch Protocol
Metformin MR to low cost branded generic (Sukkarto SR) Switch Protocol Applies to HaRD CCG employed Pharmacists and Medicines Optimisation Technicians. These protocols are produced by the NY&AWC MM team
More informationSetting The setting was primary and secondary care. The economic study was carried out in Canada.
Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective Tarride J E, Gordon A, Vera-Llonch
More informationPROCEDURE REF NO SABP/EXECUTIVE BOARD/0017
PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017 NAME OF GUIDELINE REASON FOR GUIDELINE WHAT THE GUIDELINE WILL ACHIEVE? WHO NEEDS TO KNOW ABOUT IT? Medicines Guideline: Hypnotic Medication Compliance with NICE
More informationAppendix 4C: Guidance on the Management of Chronic Non- Malignant Pain
Appendix 4C: Guidance on the Management of Chronic Non- Malignant Pain Chronic Pain Patient reporting persistent pain not responded to treatment > 3months. Serious causes should be excluded Pain is a complex
More informationCosting report: Lipid modification Implementing the NICE guideline on lipid modification (CG181)
Putting NICE guidance into practice Costing report: Lipid modification Implementing the NICE guideline on lipid modification (CG181) Published: July 2014 This costing report accompanies Lipid modification:
More informationBerkshire West Area Prescribing Committee Guidance
Guideline Name Berkshire West Area Prescribing Committee Guidance Date of Issue: September 2015 Review Date: September 2017 Date taken to APC: 2 nd September 2015 Date Ratified by GP MOC: Guidelines for
More informationFREEDOM OF INFORMATION ACT 2000 Dudley CCG: Prescribing of Antibiotics Ref: RFI0861
Freedom of Information Team Dudley CCG 17 November 2017 2nd Floor, Brierley Hill Health and Social Care Centre Venture Way Brierley Hill DY5 1RU FREEDOM OF INFORMATION ACT 2000 Dudley CCG: Prescribing
More informationJob Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014
PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN FORTH VALLEY Protocol Number 445 Version 1 Date protocol prepared: June 2014 Date protocol due
More informationCLINICAL AUDIT. Renal Function Testing in People. Taking Dabigatran
CLINICAL AUDIT Renal Function Testing in People Taking Dabigatran Valid to December 2017 bpac nz better medicin e Background Dabigatran is an oral anticoagulant used primarily to prevent stroke in people
More informationMore than 90% of all LYRICA prescriptions are approved for patients with Commercial or Medicare coverage *
DID YOU KNOW? More than 90% of all LYRICA prescriptions are approved for patients with Commercial or Medicare coverage * With the right resources, access for LYRICA (pregabalin) Capsules CV can be simple
More informationCommon Antidepressant Medications for Adults
(and Citalopram (Celexa) Escitalopram (Lexapro) Fluoxetine (Prozac) Fluoxetine Weekly (Prozac Weekly) 20 in AM w/ food (10 mg in elderly or those w/ panic disorder) 20 40 40 (If age >60yo, max 20) 10 10
More informationContributes to CQC Outcome number: 9&12 Consulted With Post/Committee/Group Date. Pharmacist. Alison Felton Head of Pharmacy/Deputy Chief.
Prescribing paracetamol in adult inpatients at MEHT Type: Clinical Guideline Register No: 18005 Status: Public on ratification Developed in response to: In line with Basildon Contributes to CQC Outcome
More informationAppendix C Factors to consider when choosing between anticoagulant options and FAQs
Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened
More informationShared Care Guidance. Vigabatrin
North of Tyne Area Prescribing Committee Shared Care Guidance Vigabatrin July 2014 (Review date July 2016) This guidance has been prepared and approved for use in Newcastle, North Tyneside and Northumberland.
More informationDrug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression
SHARED CARE PROTOCOL AND INFORMATION FOR GPS Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression Version:
More informationCapecitabine Oxaliplatin 21 day cycle (XELOX)
Systemic Anti Cancer Treatment Protocol Capecitabine Oxaliplatin 21 day cycle (XELOX) PROTOCOL REF: MPHAXELOX (Version No: 1.0) Approved for use in: Adjuvant colorectal cancer stage 3 or high risk stage
More informationA New Approach to Addressing the Heart Failure Challenge in Primary Care within the Western Locality of NEW DEVON CCG
A New Approach to Addressing the Heart Failure Challenge in Primary Care within the Western Locality of NEW DEVON CCG Dr Rosie Heath GP Principal Church view medical centre and GPwSI Western locality Cardiology
More informationBrian Kahan, D.O. FAAPMR, DABPM, DAOCRM, FIPP Center for Pain Medicine and Physiatric Rehabilitation 2002 Medical Parkway Suite 150 Annapolis, MD
Brian Kahan, D.O. FAAPMR, DABPM, DAOCRM, FIPP Center for Pain Medicine and Physiatric Rehabilitation 2002 Medical Parkway Suite 150 Annapolis, MD 1630 Main Street Suite 215 Chester, MD 410-571-9000 www.4-no-pain.com
More informationApplication for Endorsement of CQI (Clinical Audit) Activities for MOPS Credits Allocation
Application for Endorsement of CQI (Clinical Audit) Activities for MOPS Credits Allocation Below is the form you need to fill out. NAME Dianne Vicary Health Hawke s Bay DATE JUNE 2012 TITLE OF ACTIVITY
More informationSYNOPSIS. Study Coordinator. Study centre(s)
Drug product: Seroquel Drug substance(s): Quetiapine Document No.: 1 Edition No.: 1 Study code: D1449C00005 Date: 02 January 2007 SYNOPSIS A Randomized, Parallel Group, Open Trial Examining the Safety,
More informationExecutive Summary Pregabalin (Lyrica by Pfizer) Formulary Review
Executive Summary Pregabalin (Lyrica by Pfizer) Formulary Review Lyrica (pregabalin) is a new prescription medication indicated for use in painful diabetic peripheral neuropathy (DPN), post-herpetic neuralgia,
More informationFencino patch (5) 2. Check the practice has agreed to the protocol and a signed copy is in place.
Switch protocol: Fentanyl/Durogesic patches to Fencino /Matrifen /Mezolar brand switch Applies to HaRD CCG employed Pharmacists and Medicines Optimisation Technicians. These protocols are produced by the
More informationReview of bisphosphonate prescribing May 2014
Title of Project: NHS Dumfries & Galloway Review of bisphosphonate prescribing May 2014 1 Reason for the review The aim of this audit is to review patients prescribed a bisphosphonate for the prophylaxis
More informationTIAGABINE. THERAPEUTICS Brands Gabitril see index for additional brand names. Generic? Yes
TIAGABINE THERAPEUTICS Brands Gabitril see index for additional brand names Generic? Yes Class Anticonvulsant; selective GABA reuptake inhibitor (SGRI) Commonly Prescribed for (bold for FDA approved) Partial
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Methylphenidate in the treatment of Attention Deficit Hyperactivity Disorder in Children, Young People and Adults Implementation Date: June 2015 Review Date: June 2017 This guidance
More informationPFIZER INC. Study Initiation Date and Primary Completion or Completion Dates: 11 November 1998 to 17 September 1999
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationTechnology appraisal guidance Published: 26 January 2011 nice.org.uk/guidance/ta213
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years Technology appraisal guidance Published: 26 January 2011 nice.org.uk/guidance/ta213 NICE 2018. All rights reserved. Subject
More information-Guidelines for the discontinuation of oral antipsychotics in patients with BPSD within the primary care setting Summary- Quetiapine
-Guidelines for the discontinuation of oral antipsychotics in patients with BPSD within the primary care setting Summary- Quetiapine An independent report Time for action 1 by Professor Sube Banerjee looked
More informationGET THE MOST FROM YOUR LYRICA TREATMENT
GET THE MOST FROM YOUR LYRICA TREATMENT Answers and information to help you get started on LYRICA. Please see Full Prescribing Information, including Medication Guide, starting on page 8 of this PDF. Please
More informationGENERIC MEDICINES (Non-Innovator Brand) PRESCRIBING POLICY
GENERIC MEDICINES (Non-Innovator Brand) PRESCRIBING POLICY First issued by/date Issue Version Purpose of Issue/Description of Change Planned Review Date August 2018 1.0 Promoting generic prescribing whenever
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationNeuropathic Pain. Griffith Research Online. Author. Published. Journal Title. Copyright Statement. Downloaded from. Link to published version
Griffith Research Online https://research-repository.griffith.edu.au Neuropathic Pain Author Hall, Tony Published 2010 Journal Title Australian Journal of Pharmacy Copyright Statement Copyright 2010 Australian
More informationPRESCRIBING INCENTIVE SCHEME 2018/19
PRESCRIBING INCENTIVE SCHEME 2018/19 Summary Harrogate and Rural District CCG is continuing to offer a prescribing incentive scheme to all its member NHS GP practices as encouragement and reward to improve
More informationLYRICA FOR THE TREATMENT OF NEUROPATHIC PAIN DISORDERS
Volume 20, Issue 7 April 2005 LYRICA FOR THE TREATMENT OF NEUROPATHIC PAIN DISORDERS Tanja Lepir, Pharm.D. Candidate Nervous system dysfunction leading to neuropathic pain can occur from many causes: infection,
More informationNHS Dumfries & Galloway Aspirin Discontinuation Audit May 2011 (updated August 2015)
Title of Project: NHS Dumfries & Galloway Aspirin Discontinuation Audit May 2011 (updated August 2015) 1 Reason for the review In the UK, low dose aspirin (75mg) is licensed for the prevention of thrombotic
More informationCapecitabine Oxaliplatin 21 day cycle (CAPOX)
Systemic Anti Cancer Treatment Protocol Oxaliplatin 21 day cycle (CAPOX) PROTOCOL REF: MPHACAPOX (Version No: 1.0) Approved for use in: Adjuvant colorectal cancer stage 3 or high risk stage 2 Advanced
More informationRegional Renal Training
Regional Renal Training Palliative and End of Life Care Dr Clare Kendall North Bristol NHS Trust Advanced Kidney Disease Dialysis/Transplant Conservative Management Deteriorating despite dialysis/failing
More informationIt is also an option for those with Ph+ve CML who initially present in accelerated phase or with blast crisis 1.
Imatinib (Glivec ) Indications 1 Imatinib is recommended as first line treatment for people with Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase 1. It is also an
More informationOverview of Essentials of Pain Management. Updated 11/2016
0 Overview of Essentials of Pain Management Updated 11/2016 1 Overview of Essentials of Pain Management 1. Assess pain intensity on a 0 10 scale in which 0 = no pain at all and 10 = the worst pain imaginable.
More informationPaliperidone Palmitate 3-monthly Long-Acting Injection (Trevicta ) Guidelines for Prescribing and Administration (Version 1 October 2016)
Paliperidone Palmitate 3-monthly Long-Acting Injection (Trevicta ) Guidelines for Prescribing and Administration (Version 1 October 2016) 1. Key Points 1.1 Paliperidone palmitate 3-monthly long-acting
More informationBortezomib, Thalidomide & Dexamethasone
DRUG ADMINISTRATION SCHEDULE Cumbria, Northumberland, Tyne & Wear Area Team Day Drug Dose Route Diluent Rate 1, 4, 8, & 11 2 Bortezomib 1.3mg/m IV bolus/ SC injection* None Fast bolus: 3 to 5 seconds 1
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 27 May 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 May 2009 CARDENSIEL 1.25 mg, film-coated tablet B/30 (CIP code: 352 968-1) CARDENSIEL 2.5 mg, film-coated tablet
More informationLondon Medicines Information Service
London Medicines Information Service Extended-release methylphenidate a review of the pharmacokinetic profiles available March 2018 First authored by Martin Bradley (martin.bradley@gstt.nhs.uk) May 2016
More informationConservative Management of Uraemia
Conservative Management of Uraemia Information for Health Professionals Renal Department The York Hospital and Scarborough Hospital Tel: 01904 725370 For more information, please contact: The Renal Specialist
More informationSwitching Tramacet to paracetamol alone or paracetamol and codeine
Bulletin 62 February 2014 Community Interest Company Switching Tramacet to paracetamol alone or paracetamol and codeine This is one of a number of bulletins providing further information on medicines contained
More informationReviewing patients using opioid medicines long-term for non-cancer pain
CLINICAL AUDIT Reviewing patients using opioid medicines long-term for non-cancer pain Valid to March 2023 bpac nz better medicin e Audit focus This audit helps primary care health professionals optimise
More informationThis was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPatient details GP details Specialist details Name GP Name Dr Specialist Name Dr R. Horton
Rationale for Initiation, Continuation and Discontinuation (RICaD) Sacubitril/Valsartan (Entresto) For the treatment of symptomatic heart failure with reduced ejection fraction (NICE TA388) This document
More information